Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company’s adjusted EPS of 63 cents beat Wall Street’s estimate of 47 cents ...

Pfizer Inc. closed 18.10% below its 52-week high of $31.54, which the company reached on July 30th.

Bullish option flow detected in Pfizer (PFE) with 33,534 calls trading, 1.3x expected, and implied vol increasing over 1 point to 27.48%. 2/7 weekly 25 calls and 2/7 weekly 27.5 calls are the most ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

BMO Capital markets analyst Evan Seigerman said Pfizer's forecast is already conservative, and with COVID products no longer seen as a core business, investor reaction to lower volumes could be muted.

Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 ...

But soon the Obama administration came down hard on such 'tax inversion' deals, changing laws such that the deal was no longer attractive to Pfizer. No signs of slowing down Despite some setbacks ...

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight ...

Pfizer has resolved a lawsuit by a conservative group that alleged that a fellowship program that the drugmaker established to boost the pipeline of Black, Latino and Native American people in ...

Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, the company has reported a Standalone Total ...

How saving with HL works How to build your emergency cash savings How much cash should you hold? View all savings insights ...